Repligen (RGEN) Financial Analysis & Valuation | Quarter Chart

Repligen (RGEN)

RGEN
Price: $114.2
Fair Value: 🔒
🔒score
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography r... more
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in b... more
Description Shares
Market Cap$6.43BExchangeNASDAQ
SectorHealthcareIndustryMedical - Instruments & Supplies
CountryUSCEOOlivier Loeillot
IPO Date1986-04-29CAGR0.15%
Employees1,778Websitewww.repligen.com
Div. YieldPayout Ratio
Buy Back Yield2.07%Total Yield2.07%
RGEN chart loading...
Fundamentals Technicals
Enterprise Value$4.63BP/E Ratio132.79
Forward P/E40.49PEG Ratio2.37
P/S Ratio6.49P/B Ratio
P/CF Ratio34.73P/FCF Ratio44.25
EPS$0.86EPS Growth 1Y-172.82%
EPS Growth 3Y-98.96%EPS Growth 5Y-96.34%
Revenue Growth 1Y14.91%Gross Margin0.11%
Operating Margin0%Profit Margin0%
ROEROA
ROCE0%Current Ratio
Quick RatioCash Ratio
Debt/EquityInterest Coverage-0.08
Altman Z ScorePiotroski Score6